Current perspectives on bisphosphonate treatment in Paget’s disease of bone

References

• PagetJOn a form of chronic inflammation of bones (osteitis deformans)Med Chir Trans1877603764.9
   PubMedGoogle Scholar
• KanisJAPathophysiology and Treatment of Paget’s Disease of Bone2nd edLondonMartin Dunitz1998
   Google Scholar
• GennariLMerlottiDMartiniGNutiRPaget’s disease of bone in ItalyJ Bone Miner Res200621Suppl 21421
   Google Scholar
• DavieMDaviesMFrancisRFraserWHoskingDTansleyRPaget’s disease of bone: a review of 889 patientsBone1999245 Suppl11S12S10321918
   PubMed Web of Science ®Google Scholar
• HoskingDMeunierPJRingeJDReginsterJYGennariCPaget’s disease of bone: diagnosis and managementBMJ199631270294914948597686
   PubMedGoogle Scholar
• CarterLCPaget’s disease: important features for the general practitionerCompendium199011116626646656682088615
   PubMedGoogle Scholar
• RousièreMMichouLCornélisFOrcelPPaget’s disease of boneBest Pract Res Clin Rheumatol20031761019104115123049
   PubMed Web of Science ®Google Scholar
• FraserWDPaget’s disease of boneCurr Opin Rheumatol1997943473549229182
   PubMedGoogle Scholar
• RalstonSHDigiovineFSGallacherSJBoyleITDuffGWFailure to detect paramyxovirus sequences in Paget’s disease of bone using the polymerase chain reactionJ Bone Miner Res1991611124312481805546
   PubMed Web of Science ®Google Scholar
• BirchMATaylorWFraserWDRalstonSHHartCAGallagherJAAbsence of paramyxovirus RNA in cultures of pagetic bone cells and in pagetic boneJ Bone Miner Res19949111168154304
   PubMed Web of Science ®Google Scholar
• HelfrichMHHobsonRPGrabowskiPSA negative search for a paramyxoviral etiology of Paget’s disease of bone: molecular, immunological, and ultrastructural studies in UK patientsJ Bone Miner Res200015122315232911127197
   PubMed Web of Science ®Google Scholar
• GherardiGLo CascioVBonucciEFine structure of nuclei and cytoplasm of osteoclasts in Paget’s disease of boneHistopathology19804163747353818
   PubMed Web of Science ®Google Scholar
• MiiYMiyauchiYHonokiKElectron microscopic evidence of a viral nature for osteoclast inclusions in Paget’s disease of boneVirchows Arch19944241991047981909
   PubMed Web of Science ®Google Scholar
• GordonMTMeeAPAndersonDCSharpePTCanine distemper virus transcripts sequenced from pagetic boneBone Miner19921921591741345324
   PubMedGoogle Scholar
• DuránASerranoMLeitgesMThe atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesisDev Cell20046230330914960283
   PubMed Web of Science ®Google Scholar
• ReaSLWalshJPWardLA novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget’s disease of bone with a severe phenotypeJ Bone Miner Res20062171136114516813535
   PubMed Web of Science ®Google Scholar
• LayfieldRSearleMSDisruption of ubiquitin-mediated processes in diseases of the brain and boneBiochem Soc Trans200836Pt 346947118481983
   PubMedGoogle Scholar
• LayfieldRThe molecular pathogenesis of Paget disease of boneExpert Rev Mol Med200792711317903332
   PubMedGoogle Scholar
• WhyteMPObrechtSEFinneganPMOsteoprotegerin deficiency and juvenile Paget’s diseaseN Engl J Med2002347317518412124406
   PubMed Web of Science ®Google Scholar
• AltmanRDBlochDAHochbergMCMurphyWAPrevalence of Paget’s disease of bone in the United StatesJ Bone Miner Res200015346146510750560
   PubMed Web of Science ®Google Scholar
• DetheridgeFMGuyerPBBarkerDJEuropean distribution of Paget’s disease of boneBr Med J (Clin Res Ed)1982285634710051008
   PubMedGoogle Scholar
• WatWZCheungWSLauTWA case series of Paget’s disease of bone in ChineseHong Kong Med J201319324224823568934
   PubMed Web of Science ®Google Scholar
• PoórGDonáthJFornetBCooperCEpidemiology of Paget’s disease in Europe: the prevalence is decreasingJ Bone Miner Res200621101545154916995808
   PubMed Web of Science ®Google Scholar
• CundyTIs Paget’s disease of bone disappearing?Skeletal Radiol200635635035116570174
   PubMed Web of Science ®Google Scholar
• ShakerJLPaget’s disease of bone: a review of epidemiology, pathophysiology and managementTher Adv Musculoskelet Dis20091210712522870432
   PubMedGoogle Scholar
• RalstonSHClinical practice. Paget’s disease of boneN Engl J Med2013368764465023406029
   PubMed Web of Science ®Google Scholar
• DoyleFHBanksLMPennockJMRadiologic observations on bone resorption in Paget’s diseaseArthritis Rheum19802310120512146775645
   PubMedGoogle Scholar
• LangstonALCampbellMKFraserWDMacLennanGSSelbyPLRalstonSHPRISM Trial GroupRandomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget’s disease of boneJ Bone Miner Res2010251203119580457
   PubMed Web of Science ®Google Scholar
• ReidIRCundyTBollandMJGreyAResponse to publication of PRISM trialJ Bone Miner Res201025614631464 author reply 146520499373
   PubMed Web of Science ®Google Scholar
• Current Controlled TrialsZoledronate in the Prevention of Paget’s: the ZiPP study ISRCTN11616770 [webpage on the Internet]LondonCurrent Controlled Trials2008 [updated June 26, 2012]. Available from: http://www.controlled-trials.com/ISRCTN11616770Accessed September 23, 2014
   Google Scholar
• WidlerLJaeggiKAGlattMHighly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa)J Med Chem200245173721373812166945
   PubMed Web of Science ®Google Scholar
• MillerPDBrownJPSirisESHoseyniMSAxelrodDWBekkerPJA randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone. Paget’s Risedronate/Etidronate Study GroupAm J Med1999106551352010335722
   PubMed Web of Science ®Google Scholar
• SirisEWeinsteinRSAltmanRComparative study of alendronate versus etidronate for the treatment of Paget’s disease of boneJ Clin Endocrinol Metab19968139619678772558
   PubMed Web of Science ®Google Scholar
• PapapoulosSEEekhoffEMZwindermanAHAcquired resistance to bisphosphonates in Paget’s disease of boneJ Bone Miner Res200621Suppl 28891
   Google Scholar
• WalshJPWardLCStewartGOA randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget’s disease of boneBone200434474775415050907
   PubMed Web of Science ®Google Scholar
• MerlottiDGennariLMartiniGComparison of different intravenous bisphosphonate regimens for Paget’s disease of boneJ Bone Miner Res200722101510151717605632
   PubMed Web of Science ®Google Scholar
• ReidIRMillerPLylesKComparison of a single infusion of zoledronic acid with risedronate for Paget’s diseaseN Engl J Med2005353989890816135834
   PubMed Web of Science ®Google Scholar
• HoskingDLylesKBrownJPLong-term control of bone turnover in Paget’s disease with zoledronic acid and risedronateJ Bone Miner Res200722114214817032148
   PubMed Web of Science ®Google Scholar
• ReidILylesKWSuGLong-term efficacy of zoledronic acid compared with risedronate in Paget’s diseaseBone201047Suppl 1OC21
   Google Scholar
• WoitgeHWOberwittlerHHeichelSGrauerAZieglerRSeibelMJShort- and long-term effects of ibandronate treatment on bone turnover in Paget disease of boneClin Chem200046568469010794751
   PubMed Web of Science ®Google Scholar
• ReidIROsteoporosis treatment: focus on safetyEur J Intern Med201324869169723608531
   PubMed Web of Science ®Google Scholar
• Aclasta™ (zoledronic acid) [package insert]BaselNovartis2011
   Google Scholar
• KwekEBGohSKKohJSPngMAHoweTSAn emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?Injury200839222423118222447
   PubMed Web of Science ®Google Scholar
• LenartBALorichDGLaneJMAtypical fractures of the femoral diaphysis in postmenopausal women taking alendronateN Engl J Med2008358121304130618354114
   PubMed Web of Science ®Google Scholar
• FeldmanFAtypical diaphyseal femoral fractures – new aspectsSkeletal Radiol2012411758121369720
   PubMed Web of Science ®Google Scholar
• Park-WyllieLYMamdaniMMJuurlinkDNBisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older womenJAMA2011305878378921343577
   PubMed Web of Science ®Google Scholar
• BlackDMKellyMPGenantHKFracture Intervention Trial Steering CommitteeHORIZON Pivotal Fracture Trial Steering CommitteeBisphosphonates and fractures of the subtrochanteric or diaphyseal femurN Engl J Med2010362191761177120335571
   PubMed Web of Science ®Google Scholar
• NievesJWBilezikianJPLaneJMFragility fractures of the hip and femur: incidence and patient characteristicsOsteoporos Int201021339940819484169
   PubMed Web of Science ®Google Scholar
• AbrahamsenBEikenPEastellRSubtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort studyJ Bone Miner Res20092461095110219113931
   PubMed Web of Science ®Google Scholar
• AbrahamsenBEikenPEastellRCumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysisJ Clin Endocrinol Metab201095125258526520843943
   PubMed Web of Science ®Google Scholar
• MeierRPPernegerTVSternRRizzoliRPeterREIncreasing occurrence of atypical femoral fractures associated with bisphosphonate useArch Intern Med20121721293093622732749
   PubMed Web of Science ®Google Scholar
• DellRMAdamsALGreeneDFIncidence of atypical nontraumatic diaphyseal fractures of the femurJ Bone Miner Res201227122544255022836783
   PubMed Web of Science ®Google Scholar
• WooSBHellsteinJWKalmarJRNarrative [corrected] review: bisphosphonates and osteonecrosis of the jawsAnn Intern Med20061441075376116702591
   PubMed Web of Science ®Google Scholar
• KhoslaSBurrDCauleyJAmerican Society for Bone and Mineral ResearchBisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res200722101479149117663640
   PubMed Web of Science ®Google Scholar
• SchwarzPRasmussenAQKvistTMAndersenUBJørgensenNRPaget’s disease of the bone after treatment with Denosumab: a case reportBone20125051023102522586699
   PubMed Web of Science ®Google Scholar
• GrasemannCSchündelnMMHövelMEffects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget’s diseaseJ Clin Endocrinol Metab20139883121312623788687
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyEuropean Medicines Agency recommends limiting long-term use of calcitonin medicines [press release]LondonEuropean Medicines Agency2012 [July 20]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/07/WC500130122.pdfAccessed September 23, 2014
   Google Scholar
• LevyFMuffRDotti-SigristSDambacherMAFischerJAFormation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget’s diseaseJ Clin Endocrinol Metab19886735415453410939
   PubMed Web of Science ®Google Scholar